NCT04208035 (CELINE) is a clinical trial in Chronic Hepatitis c, sponsored by Radboud University Medical Center.

Who is sponsoring NCT04208035?

NCT04208035 is sponsored by Radboud University Medical Center.

What condition does NCT04208035 study?

NCT04208035 studies Chronic Hepatitis c.

Is NCT04208035 still recruiting?

NCT04208035 is currently status unknown. Last updated 23 December 2019.

Last reviewed 2019-12-23 · How we verify

NCT04208035: CELINE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hepatitis C Elimination in the Netherlands

Status unknown Last updated 23 December 2019

What this trial tests

trial in Chronic Hepatitis c in 250 participants. Status unknown.

Timeline

17 September 2018

Primary endpoint
1 January 2021

1 January 2021

Quick facts

Lead sponsor	Radboud University Medical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	250
Start date	17 September 2018
Primary completion	1 January 2021
Estimated completion	1 January 2021
Sites	1 location across Netherlands

Conditions studied

Chronic Hepatitis c — all drugs for Chronic Hepatitis c →

Sponsor

Radboud University Medical Center

Who can join

18 and older, any sex, with Chronic Hepatitis c. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of CELINE is to retrieve and re-evaluate lost to follow-up chronic hepatitis C patients in the Netherlands.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C.
Isfordink CJ, Brakenhoff SM, van Dijk M, van der Valk M, et al · · 2020 · cited 12× · PMID 32377367 · DOI 10.1136/bmjgast-2020-000396

Verify or expand the search:

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04208035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 23 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04208035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing